- Home
- PAVM vs AEON Comparison
PAVM vs AEON Comparison
Compare PAVM & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- AEON
- Stock Information
- Founded
- PAVM 2014
- AEON N/A
- Country
- PAVM United States
- AEON United States
- Employees
- PAVM N/A
- AEON N/A
- Industry
- PAVM Medical/Dental Instruments
- AEON Biotechnology: Pharmaceutical Preparations
- Sector
- PAVM Health Care
- AEON Health Care
- Exchange
- PAVM Nasdaq
- AEON Nasdaq
- Market Cap
- PAVM 8.0M
- AEON 8.0M
- IPO Year
- PAVM 2016
- AEON N/A
- Fundamental
- Price
- PAVM $0.40
- AEON $0.76
- Analyst Decision
- PAVM Strong Buy
- AEON Strong Buy
- Analyst Count
- PAVM 1
- AEON 1
- Target Price
- PAVM $19.00
- AEON $360.00
- AVG Volume (30 Days)
- PAVM 268.2K
- AEON 77.4K
- Earning Date
- PAVM 11-12-2025
- AEON 11-12-2025
- Dividend Yield
- PAVM N/A
- AEON N/A
- EPS Growth
- PAVM N/A
- AEON N/A
- EPS
- PAVM 0.83
- AEON N/A
- Revenue
- PAVM $1,020,000.00
- AEON N/A
- Revenue This Year
- PAVM N/A
- AEON N/A
- Revenue Next Year
- PAVM $455.63
- AEON N/A
- P/E Ratio
- PAVM $0.50
- AEON N/A
- Revenue Growth
- PAVM N/A
- AEON N/A
- 52 Week Low
- PAVM $0.30
- AEON $0.38
- 52 Week High
- PAVM $1.90
- AEON $115.57
- Technical
- Relative Strength Index (RSI)
- PAVM 35.48
- AEON 51.06
- Support Level
- PAVM $0.42
- AEON $0.72
- Resistance Level
- PAVM $0.45
- AEON $0.81
- Average True Range (ATR)
- PAVM 0.04
- AEON 0.05
- MACD
- PAVM -0.00
- AEON 0.00
- Stochastic Oscillator
- PAVM 3.02
- AEON 57.91
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.